Background
==========

gPRA is usually inherited as an ar blinding disorder with different ages of onset and variable rate of progression observed in more than 100 dog breeds. Typically, gPRA commences with degeneration of the rod photoreceptors. Initial signs include night blindness whereas progression involves the cones and the central vision \[[@B1],[@B2]\]. The human equivalent of canine gPRA is termed retinitis pigmentosa (RP). RP comprises a large and genetically heterogeneous group of blinding disorders. RP may be inherited in an ar, dominant, X-linked, digenic or maternal mode \[[@B3]-[@B7]\]. Similarly in dogs, at least 4 genes were identified so far as causing gPRA in 6 breeds. All of these genes encode photoreceptor specific proteins involved in the visual transduction cascade including the β-subunit of the cGMP-specific phosphodiesterase (PDE6B) in Irish Setters and Sloughis \[[@B8],[@B9]\] as well as the α-subunit of the cGMP-specific phosphodiesterase (PDE6A) in Cardigan Welsh Corgis \[[@B10]\]. A missense mutation was detected in the *PDC* gene that may be associated with photoreceptor dysplasia, a form of gPRA in the Miniature Schnauzer \[[@B11]\]. The X-linked form of PRA in Samoyed and Siberian Husky is caused by mutations in the *RPGR* gene \[[@B12]\]. Recently in English Mastiff dogs an autosomal dominantly transmitted form of gPRA was identified, mimicking human RP. The disease causing mutation is a T4R exchange in the *rhodopsin* (*RHO*) gene \[[@B13]\]. A number of other retinal genes have been excluded as harbouring mutations for gPRA in several dog breeds: RHO; \[[@B14]\], *RDS/peripherin* and *ROM*-1 \[[@B15]\] as well as the α -- and γ-subunits of *transducin*\[[@B16]\] and *SAG*\[[@B17]\]. Yet, the *SAG* gene had been analyzed on the exonic level exclusively, *i.e.* by sequencing of cDNA. The human *SAG* gene comprises 16 exons ranging in size between 243 and 10 bp. SAG protein (403 amino acids) has been identified only in retinal photoreceptor rods and pinealocytes \[[@B18]\].

SAG belongs to a family of inhibitory proteins that bind to tyrosine-phosphorylated receptors, thereby blocking their interaction with G-proteins and effectively terminating the signalling chain. In the phototransduction cascade, SAG and rhodopsin kinase (RHOK) act together in the recovery phase of RHO. After photoactivation, RHOK phosphorylates photoexited RHO which is then blocked by SAG binding thus inhibiting its ability to interact with transducin \[[@B19],[@B20]\]. The existence of stable complexes between RHO and its regulatory protein SAG were demonstrated to be responsible for retinal degeneration in several mutations in Drosophila \[[@B21]\]. Accumulation of these complexes triggers apoptotic cell death showing that retinal degeneration requires the endocytic machinery (*op. cit.*). Interestingly, loss of function in the *SAG* gene causes ar inherited Oguchi disease in Japanese, a variant of congenital stationary night blindness \[[@B22],[@B23]\]. Apparently the mutation causing Oguchi disease can also lead to arRP in Japanese families \[[@B24]\]. Here we report on the identification of intronic sequences and mutation screening of the canine photoreceptor-specific *SAG* gene in 19 different dog breeds.

Results and Discussion
======================

Genomic organization of the SAG gene
------------------------------------

The screening of the canine genomic library with probes for exons 2, 5 and 16 led to the isolation of seven DNA clones, each containing different parts of the *SAG* gene. This gene contains 16 exons with the 5\'*UTR* split into exons 1 (156 bp) and in 2 (57 bp). The 3\'*UTR* is comprised in exon 16 (137 bp). The coding region is 1215 bp long. Most introns were longer than 1.5 kb (Table [2](#T2){ref-type="table"}). Compared to the human *SAG* gene the position of intron 1, which is in the 5\'UTR, is 23 bp further upstream in the dog. This means the canine exon 1 is 23 bp shorter and exon 2 23 bp longer than the equivalent human exons. In dogs exon 15 is 6 bp longer and exon 16 6 bp shorter than the equivalent exons in human. Therefore, the predicted protein in both species are 405 aa long and have a similarity of 89.8%. The intron sizes in man and dog differ, leading to gene sizes of \~ 35 kb in dog and \~ 40 kb in man. The splice donor and acceptor sites follow the GT/AG rule (Table [2](#T2){ref-type="table"}). Canoidea-specific, tRNA-derived short interspersed nucleotide elements (SINE; \[[@B25]\]) were identified in introns 1, 3 and 14 and additional repetitive elements in introns 2, 3 and 14. The human *SAG* gene maps to chromosome 2q37.1. On the basis of reciprocal chromosome painting \[[@B26]\], the canine gene is, therefore, predicted to map to CFA 28 or 33, the homologous chromosomal regions in dogs.

###### 

Characteristics of dog breeds examined

  **Breed (abbreviation)**        **Number of dogs**   **Diagnosis**   **Onset forms of gPRA**   **Age distribution (year)^f^**
  ------------------------------- -------------------- --------------- ------------------------- --------------------------------
  Afghan Hound (AW)               1                    gPRA-affected   late^b^                   6
                                  4                    normal                                    2--12
  Australian Cattle dogs (AC)     2                    gPRA-affected   late^a^                   10
                                  19                   normal                                    2--4
  Berger des Pyrénées (BDP)       1                    gPRA-affected   mid-onset^b^              5
                                  42                   normal                                    1--10
  Berner Sennenhund (BS)          1                    gPRA-affected   late^b^                   10
  Bolognese (Bo)                  1                    gPRA-affected   late^b^                   9
  Collie (Co)                     3                    gPRA-affected   early^cd^                 4--8
                                  1                    normal                                    8
  Curly Coated Retriever (CCR)    1                    gPRA-affected   late^b^                   6
  Dachshund (wire; D)             20                   gPRA-affected   variable^b^               1--13
                                  49                   normal                                    6--13
  Engl. Cocker Spaniel (ECS)      6                    gPRA-affected   late^cd^                  3--11
                                  6                    normal                                    6--14
  English Springer Spaniel (SP)   1                    gPRA-affected                             7
  Entlebucher Mountain Dog (EM)   17                   gPRA-affected   late^e^                   5--13
                                  10                   normal                                    1--7
  Giant Schnauzer (GS)            1                    gPRA-affected   late^b^                   10
  Golden Retriever (GR)           2                    gPRA-affected   late^b^                   5--10
                                  8                    normal                                    3--6
  Irish Setter (IRS)              2                    gPRA-affected   early^cd^/late^b^         0.6--7
                                  1                    normal                                    3--13
  Labrador Retriever (LR)         5                    gPRA-affected   late^cd^                  8--12
                                  140                  normal                                    3--13
  Miniature poodle (MP)           28                   gPRA-affected   late^cd^                  5--12
                                  15                   normal                                    1--12
  Newfoundland Dog (NF)           1                    gPRA-affected   mid-onset^b^              3
  Polski Owczarek Nizinny (PON)   1                    gPRA-affected   late^b^                   9
  Rottweiler (Ro)                 1                    gPRA-affected   late^b^                   3
  Saarloos/Wolfhond (Sa)          7                    gPRA-affected   late^b^                   7--9
                                  118                  normal                                    2--10
  Schapendoes (SD)                3                    gPRA-affected   early^d^                  2--6
                                  7                    normal                                    3--6
  Sloughi (Sl)                    5                    gPRA-affected   mid-onset^b^              2
                                  183                  normal                                    0.1--12
  Tibetan Terrier (TT)            3                    gPRA-affected   mid-onset^cd^             7--8
                                  93                   normal                                    2--10

^a^\[[@B34]\]. ^b^ owners report/certificate of eye examination. ^c^ classifications of the different onset forms of gPRA in the reviews \[[@B1]\] and \[[@B2]\]. ^d^ online information among PRA Today <http://www.sheepdog.com/diseases/pra/clinical>. ^e^\[[@B35]\]. ^f^ at the time when blood was taken for DNA analysis.

###### 

Primers for the characterization of the SAG gene

  ----------------------------------------------------------------------------------------------------------------
  **Exon**   **Forward primer,**\            **Exon (\#)**\      **Intron**\     **splice donor site (*gt*),**\
             **reverse primer (5\'--3\')**   **and size (bp)**   **size (bp)**   **splice acceptor site (*ag*)**
  ---------- ------------------------------- ------------------- --------------- ---------------------------------
  1--2       GGGCAACCCTGTCCAGG               \(1\) 156           836             

             ACACCCTGGGGTCTGTGTC                                                 CACAAG**gt**acatg

  2--3       AGTGAAAGAAGCTACCAGGGA           \(2\) 132           \~ 5500         ttccc**ag**CTTGCT

             ACCCACAGGCTCTACTTGT                                                 AAGTCG**gt**aagtgg

  3--4       AGGTGACCATCTACTTGGG             \(3\) 61            \~ 2600         cctat**ag**GTGACC

             AAAGTTCTTTCCTAGCACTAAG^a^                                           CTGTGG**gt**aagttg

  4--5       AGATGGTATCGTGTTGGTGG            \(4\) 45            \~ 1800         ggttt**ag**ATGGTA

             ACCGTGAGCAGGAAGGG                                                   AGAAAG**gt**aagaca

  5--6       AGTGTATGTCTCTCTGACCTG           \(5\) 194           \~ 2000         cctcc**ag**TGTATGT

             ACCTTCCCCATGTCTTGCG                                                 CTCACG**gt**gggtg

  6--7       CAAGTTTTACACACTGAGTGC^a^        \(6\) 60            \~ 1300         cccac**ag**TTCCCTG

             TCGCAGGCCACAGAGGAGAAG^a^                                            GGGAAG**gt**tagtg

  7--8       GTGCTGTGGGGTCGACTTT             \(7\) 77            \~ 1500         actgc**ag**TGCTGTG

             CAGCACCCACAGCAGATTG^a^                                              CAAGAA**gt**aagagt

  8--9       AGGAGGTCCGTGCGTTTTAC            \(8\) 136           905             tctgc**ag**GAGCTCC

             CTAATGCCTTTAATCTTCTTC                                               AAAGAG**gt**gagcca

  9--10      CCTAGAAAGCCATGAGATTAAA^a^       \(9\) 85            \~ 1500         ttttc**ag**ATCTATT

             AAGCCAAGCATCCTACTTCC                                                CATTAG**gt**aggaac

  10--11     TGGAACAAGTGGCCAACGTT^a^         \(10\) 73           \~ 2500         tctgc**ag**TGGAACA

             ACATGGTGCTGCAAGG                                                    AACACA**gt**gagtag

  11--12     GGACTGATGGTGGCTTTATG^a^         \(11\) 138          \~ 3200         cctac**ag**AGAAAAA

             ACCCTGACACCGTGAGCTTC                                                CACCAT**gt**gagtcc

  12--13     TGAGGGATGTGTTCATCTAG^a^         \(12\) 78           1390            tgagc**ag**AATAAAG

             TTCATAACACCTCTGAGCTAC^a^                                            GTCAGG**gt**gagtgt

  13--14     CTGGAGGTGAGCTCTCCCA             \(13\) 24           \~ 1400         ttcct**ag**CTTTCTG

             GTGCTCAGGGACCACTAG                                                  CTCCAG**gt**aagcct

  14--15     AGTGAAGTGGCAACTGAGGT            \(14\) 56           \~ 3000         tttcc**ag**TGAAGTG

             AAGCCGAAGACTGGGAGCa                                                 ACCCAG**gt**cagtcg

  15--16     CCTGCTCACGATTCTCTTTC            \(15\) 16           426             cttac**ag**CTACGGC

             GTCCAGGTCGACCGACCT                                                  GGAAAG**gt**gagccc

                                             \(16\) 237                          tctttt**ag**TTTTCA
  ----------------------------------------------------------------------------------------------------------------

PCR amplification of the canine *SAG* gene: primers for the identification of exon/intron boundaries and for the determination of intronic lengths of the canine genomic *SAG* clones (exon sequences are shown in upper case) ^a^the intronic sequences of the *SAG* gene received the EMBL accessions numbers AJ426068-AJ426078

Mutation screening by PCR-SSCP analysis
---------------------------------------

The *SAG* gene was screened for mutations in 23 breeds, including all gPRA-affected, selected healthy dogs as well as obligatory carriers. The 16 exons were analysed by PCR-SSCP including all intronic splice signal sequences as well as the *UTR*s (*i.e.* complete cDNA plus \>3070 bp of the introns). In the coding region of the *SAG* gene, 5 polymorphisms were identified that result in altered amino acid coding (H14C, A111V, A113T, D259T and A379E), and 7 silent polymorphisms were identified (C132C, Q199Q, H225H, V247V, P264P, T288T and L293L; Table [4](#T4){ref-type="table"}). In addition, 13 sequence variations were identified in 9 introns of gPRA affected and unaffected animals (Table [4](#T4){ref-type="table"}). Several gPRA-affected dogs in 14 of the 23 breeds were heterozygous for one of the aforementioned polymorphisms (Table [4](#T4){ref-type="table"}). In 6 of these 14 dog breeds the major cause of gPRA has meanwhile been determined. Direct DNA tests are possible for Irish Setters and Sloughis \[[@B8],[@B9]\]. Indirect tests for progressive rod cone degeneration (*prcd*) were recently offered for Australian cattle dogs, English Cocker Spaniels, Labrador Retrievers and Miniature poodles (patented by OptiGen, USA). These dog breeds were included as controls to characterise the identified polymorphisms to exclude linkage for causal gPRA mutations. A second gPRA form may be exist in Irish Setter because one affected Setter shows a late form of gPRA without the typical *PDE6B* mutation. Because of the clinical signs, also in Miniature poodles two types of gPRA are possible (OptiGen).

Conclusions
===========

None of the amino acid changes identified here in dogs correspond to residues that are mutated in known RP, nor are they known to be important for binding activated dephosphorylated RHO \[[@B22],[@B23],[@B27]\]. As detailed above, Oguchi disease and some forms of arRP is caused by the deletion in codon 309 in Japanese. None of the aa exchanges in the dog breeds investigated here correspond with this region. Nevertheless, these novel sequence variations can be used as intragenic markers for segregation analyses with ar gPRA. The breeding history, small population sizes and gPRA abundance in the investigated breeds point together to few meiotic events in which intragenic recombinations could have occured between an unidentified mutation in the *SAG* locus in gPRA dogs and the polymorphisms investigated here. Given ar transmission our typing results suggest that the sequence variations in the *SAG* gene are not causative for gPRA in the following 14 dog breeds: AC, BDP, Bo, BS, ECS, D, IRS, GR, MP, NF, PON, Sa, SD and Sl. In 6 of these dog breeds only one gPRA affected animal was available for mutation analysis (Table [1](#T1){ref-type="table"}). For these breeds the exclusion of the*SAG* gene is not definitive, since the possibility of false diagnosis is not ruled out completely. Nevertheless, gPRA-affected AW, CCR, SP, LR, Ro and TT show homozygous sequence variation patterns and 3 dog breeds (Co, EM, GS) did not harbour any sequence variations. Therefore, the *SAG* gene cannot be excluded as a cause for gPRA in these breeds, especially because of mutations in the elusive regulatory regions for gene expression.

###### 

Primer sequences used for mutation analysis of individual exons/introns of the canine *SAG* gene

  **Primer**   **Location**   **Forward primer, reverse primer (5\'--3\')^a^**   **PCR conditions \[T-°C/MgCl~2~-mM\]**   **PCR amplicon length (bp)**   **Restriction enzymes for SSCP analyses**
  ------------ -------------- -------------------------------------------------- ---------------------------------------- ------------------------------ -------------------------------------------
  UTR1F        exon 1         GGGCAACCCTGTCCAGGT                                 54/1.0                                   699                            *Nla*III/*Rsa*I
  UTRI-1aR     intron 1       TCTATCATGACGGGACGCCT                                                                                                       
  UTRI-1aF     intron 1       GAAAATGATATTTGCAAAGCAG                             50/1.0^b^                                283                            *Tru*1I
  UTRI-1aR     intron 1       TCTATCATGACGGGACGCCT                                                                                                       
  1-IF         intron 1       CTAATGGGCACACAGCATCTC                              53/1.0                                   249                            *Pvu*III; *Nla*III^c^
  2-I2R        intron 2       TTCTGTTAAGCCACTCACTTC                                                                                                      
  3-IF         intron 2       TGTTTTTATCTAACACTGACTACTTC                         48/1.0^b^                                224                            *Nla*III
  3-IR         intron 3       AAATAACAAAGTAGCAGCTGTC                                                                                                     
  4-IF         intron 3       AACTGCAGATAAATATATGAAG                             52/1.0                                   189                            *Alu*I
  4-IR         intron 4       AAAGTTCTTTCCTAGCACTAAG                                                                                                     
  5-IF         intron 4       GGTTACCCCATGTTCACTTG                               56/1.0                                   343                            *Mnl*I
  5-IR         intron 5       GCTCCTGGTCACACTGCAAG                                                                                                       
  6-IF         intron 5       CAAGTTTTACACACTGAGTGC                              55/1.0                                   213                            *Alu*I
  6-IR         intron 6       ATTTTCCCCAGAGAAAAGGCTA                                                                                                     
  7-IF         intron 6       CGGGAAGGGAGGTGCTGA                                 58/1.0                                   233                            *Rsa*I^c^
  7-IR         intron 7       TCGCAGGCCACAGAGGAGAAG                                                                                                      
  8-IF         intron 7       ATCACAGCGTGAGTACGGGGAG                             55/1.0                                   288                            RsaI; *Pst*I^c^
  8-IR         intron 8       CAGCACCCACAGCAGATTG                                                                                                        
  9-IF         intron 8       CCTAGAAAGCCATGAGATTAA                              55/1.5                                   214                            *Tru*I1; *Sty*I^c^
  9-IR         intron 9       GACCAGACTGAGAAATTCTAG                                                                                                      
  10-IF        intron 9       GGCACCATGCACATGCGTG                                58/1.0                                   235                            *Alu*I
  10-IR        intron 10      AAGCCAAGCATCCTACTTCC                                                                                                       
  11-IF        intron 10      GGACTGATGGTGGCTTTATG                               58/1.0                                   266                            *BsuR*I
  11-IR        intron 11      AGCAGACCAGCACCTCCTC                                                                                                        
  12-IF        intron 11      TGAGGGATGTGTTCATCTAG                               55/1.0                                   183                            \-
  12-IR        intron 12      GCCCATGGTGTTGGCTCTTG                                                                                                       
  13-IF        intron 12      CATGCTTGGGACATGTCCAC                               64/1.0                                   209                            *Mva*I
  13-IR        intron 13      TTCATAACACCTCTGAGCTAC                                                                                                      
  14-IF        intron 13      CTCTGCAGCCACAGCCCTTC                               50/2.0                                   229                            *Ava*II
  14-IR        intron 14      GTGCTCAGGGACCACTAG                                                                                                         
  15-IF        intron 14      CCTGCTCACGATTCTCTTTC                               58/1.0                                   244                            *Hph*I
  15-IR        intron 15      AAGCCGAAGACTGGGAGC                                                                                                         
  16-IF        intron 15      GATCGGTCCCTTGTTGCA                                 52/2.0^b^                                347                            *Alu*I
  16-ER        Exon 16        CACAGCTGAACAGACAAACTT                                                                                                      

^a^See EMBL accession numbers AJ426068-AJ426078 ^b^with 5% formamide ^c^with RLFP analysis

Materials and Methods
=====================

Animals
-------

Blood from 810 dogs of 23 different breeds, including 113 gPRA-affected animals (Table [1](#T1){ref-type="table"}) was collected with the permission of the owners and in cooperation with breeding organisations. Experienced veterinarians confirmed the gPRA status of healthy and affected dogs by ophthalmoscopy.

Isolation of canine DNA and PCR
-------------------------------

DNA was extracted from peripheral blood according to standard protocols \[[@B28]\]. Portions of the *SAG* gene were amplified by PCR in a thermocycler (Biometra, Goettingen, Germany) from the inserts of the λ phages in order to obtain intronic sequences. Genomic DNAs from all gPRA-affected, obligate carrier and gPRA-unaffected dogs were screened for sequence variations. PCRs were performed in 96-well microtiter plates (Thermowell Costar Corning, NY). Each well contained 50 ng DNA in 10 μl reaction volume (100 mM Tris \[pH 8.3\], 500 mM KCl, 1 U *Taq* Polymerase \[Genecraft, Münster, Germany\], 0.2 mmol of each NTP, 0.4 mM of each primer and varying concentrations of MgCl~2~ \[Table [3](#T3){ref-type="table"}\]). For SSCP analysis, 0.06 μl of \[α^32^P\] dCTP (10 mCi/ml) was included in the PCR. Parts of the λ phage inserts were amplified in a one step PCR (annealing temperatures in Table [3](#T3){ref-type="table"}). For genomic mutation analysis PCR conditions included initial denaturation (5 min at 95°C), the 10 initial cycles 1°C above the annealing temperature (Table [3](#T3){ref-type="table"}), 22--25 cycles of 95°C (30 s), annealing temperature (30 s), elongation at 72°C (40 s) and a final elongation step at 72°C (3 min).

###### 

*SAG* sequence variations and amino acid exchanges in respective dog breeds

                                       Sequence variations in breed(s)^a^                                      
  ----------- ---------------- ------- ----------------------------------------------------------------------- ---------------------------------
  Intron 1    IVS1+393T→C      \-      BDP, BS, GR, IRS, Ro^b^, TT                                             BDP, GR,
  Exon 2      UTR-5A→G         \-      Bo, BS, GR^c^, BDP, IRS, SD^c^, Sl, TT^b^                               Bo, GR, SD
              c255A→G          H14C    SI                                                                      Sl
  Exon 5      c526C→T          A111V   Sa^c^                                                                   Sa
              c531G→A          A113T   Sa^c^                                                                   Sa
  Intron 5    IVS5-30C→T       \-      ECS, MP, Ro^b^, Sa^c^                                                   ECS, MP, Sa
  Exon 6      c610C→T          C132C   GR                                                                      GR
  Intron 7    IVS7+10C→T       \-      IRS^b^, GR, SP^c^                                                       D, IRS, GR
              IVS7+52Ins.G     \-      GR^c^                                                                   GR
              IVS7-4Del.G      \-      CCR^b^ D, GR, IRS, MP, SD^c^, Sl^c^, SP^b^, TT^c^                       D, GR, IRS, SD
  Exon 8      c811G→A          Q199Q   GR                                                                      GR
  Intron 8    IVS8+8A→G        \-      D, ECS^c^, GR^c^, LR^c^, Sa                                             D, ECS, GR, Sa
  Exon 9      c874T→C          H225H   Bo, BDP, CCR^b^, ECS, D, GR^c^, IRS, MP, NF, Ro^b^, Sa, Sl^b^, TT^bc^   Bo, ECS, D, GR, IRS, MP, NF, Sa
  Exon 10     c949G→T          V247V   IRS, GR                                                                 GR
              c983G→T          D259T   AC^b^                                                                   AC
              c1000A→G         P264P   AC, LR, IRS^b^, GR                                                      GR
  Intron 10   IVS10-18G→C      \-      GR, IRS, BDP                                                            GR
              IVS10-33C→T      \-      GR, IRS                                                                 GR
  Exon 11     c1063G→A         T288T   BS, BDP, GR, IRS^b^, Sa                                                 BS, GR, Sa
              c1076C→T         L293L   BS, BDP, GR^c^, Sa, TT                                                  BS, Sa
  Intron 11   IVS11-51Ins.TT   \-      Sa, IRS^b^                                                              Sa
  Intron 13   IVS13+66C→G      \-      Sa, IRS^b^                                                              Sa
  Intron 14   IVS14-45Del.A    \-      PON                                                                     PON
  Intron 15   IVS15+14C→T      \-      Sa                                                                      \-
              IVS15+86T→A      \-      Sa                                                                      \-
              IVS15-45Ins.C    \-      PON, AW^bc^, SP^b^                                                      PON
  Exon 16     c1344C→A         A379E   IRS^b^, ECS^b^, GR^c^, PON, Sa^bc^, TT^b^                               ECS, GR

^a^ For abbreviations see Table [1](#T1){ref-type="table"}^b^ Homozygous state in gPRA affected dogs ^c^ Homozygous state in unaffected dogs ^\*^(EMBL accession number for cDNA: X98460; EMBL accession numbers for genomic DNA: AJ426068-AJ426078)

Cloning and identification of exon/intron junctions
---------------------------------------------------

Clones containing the *SAG* gene were isolated from a genomic canine λ-DNA library (λ FIX^®^II Library; host: *E. coli* XL1-Blu MRA (P2) Stratagene, La Jolla, Ca, USA) according the manufacturer\'s protocol. Recombinant λ DNA was fixed to Hybond™-N Nylon membranes (Amersham, Buckinghamshire, UK) and UV-crosslinked (1\' 70 J/cm^2^). The library was screened with probes prepared from PCR products corresponding to portions of exons 2, 5 and 16 (nucleotides 909--1157 of EMBL accession number CFA426068, nucleotides 395--588, and 1333--1579 of EMBL accession number X98460, respectively). These probes were labelled using \[α^32^P\] dATP and the Megaprime Labelling System (Amersham, Buckinghamshire, UK). Hybridisations were performed at 65°C in 0.5 M sodium phosphate buffer (pH 7.2)/7% sodium dodecyl sulfate \[[@B29]\]. After hybridisation the filters were washed twice for 30 min each in 2× SSC/1% SDS, once for 15 min with 0.2× SSC/1%SDS at 65°C and for 30 min with 6×SSC at room temperature. The filters were exposed to phosphoimager screens (STORM 860) and evaluated with the programs STORM Scanner Control and Image Quant (Molecular Dynamics). Hybridising clones were isolated and plaque purified as described \[[@B30]\]. The approximate insert sizes of the different clones were estimated with exon primers via PCR (see conditions described above using\~0.2 ng phage DNA, 2 mM MgCl~2~ and annealing temperature of 54°C in the PCR).

Exon/intron boundaries were analysed by comparison of canine mRNA (\[[@B17]\], EMBL accession number X98460) with 16 genomic sequences of the human *SAG* gene (5\'-flanking region and exon 1 \[[@B18]\]; EMBL accession number X12453); exons 2--16 (\[[@B31]\]; EMBL accession numbers U70963-U70976) using the program Blast Search (NCBI <http://www.ncbi.nlm.nih.gov/blast>). Intronic sizes were estimated by overlapping PCR including parts of neighbouring exons. PCR products were extracted from 1.5% agarose gels using the Easy Pure extraction kit (Biozym, Germany) and sequenced with intron-overlapping primers (Table [2](#T2){ref-type="table"}). Sequencing reactions from 2--3 clones were carried out by the dideoxy-chain termination method using the BDT (Perkin-Elmer, Norwalk, CT) according to the manufacturer\'s instructions. All sequencing reactions were run on an automated DNA sequencer (Applied Biosystems 373 XL, Foster City, USA) and analysed using ABI Prism™ 373XL.

PCR-SSCP and DNA sequence analysis
----------------------------------

Positions of intronic primers which were used for mutation screening were selected after DNA sequence analysis of the genomic *SAG* clones (Table [3](#T3){ref-type="table"}). SSCP samples were treated as previously described \[[@B16],[@B32]\]. PCR products were digested dependent on the lengths of the fragments \[[@B33]\] with different restriction enzymes (Table [3](#T3){ref-type="table"}). Using restriction length fragment polymorphism (RLFP) analysis the sequence variants in exon 2 (*Nla*III), intron 7 (*Rsa*I), exon 8 (*Pst*I) and exon 9 (*Sty*I) were investigated. 3 μl of the PCRs were denatured with 7 μl of loading buffer (95% deionised formamide 10 mM NaOH, 20 mM EDTA, 0.06% (w/v) xylene cyanol, and 0.06% (w/v) bromophenol blue). The samples were heated to 95°C for 5 min and snap cooled on ice. 3 μl aliquots of the single-stranded fragments were separated in 2 sets of 6% polyacrylamide (acrylamide/bisacrylamide: 19/1) gels, one set containing 10% glycerol, another containing 5% glycerol and 1 M urea. Gels were run with 1× TBE buffer at 50--55 W for 4--6 h at 4°C. All gels were dried and subjected to autoradiography over night. Selected DNA samples with band shifts evidenced by SSCP electrophoresis were purified and cycle sequenced as described above.
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